Calliditas Therapeutics to Present at Jefferies Virtual Healthcare Conference
Calliditas Therapeutics announced its participation in the Jefferies Virtual Healthcare Conference on June 1, 2021, at 2:30 pm CET/8:30 am ET. The management will present and host 1x1 meetings during the event. Registration is available via the provided link, and the presentation will be archived for 30 days post-event. Calliditas focuses on developing treatments for orphan diseases, with its lead product candidate, Nefecon, targeting IgA nephropathy, a condition with no approved treatments. The company trades on NASDAQ under the ticker CALT.
- None.
- None.
STOCKHOLM, May 28, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that management will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:30 pm CET/8:30 am ET. Calliditas will also host 1x1 meetings during the conference. Details for the presentation are as follows:
Jefferies Virtual Healthcare Conference
Date: Tuesday, June 1, 2021
Time: 2:30 pm CET / 8:30 am ET
Registration Link: https://wsw.com/webcast/jeff174/register.aspx?conf=jeff174&page=calt&mmid=3325730&refer=meetmax&firstname=&lastname=
The webcast will be archived for a period of 30 days following the conclusion of the event.
For further information, please contact:
Marie Galay, IR Manager, Calliditas
Tel.: +44 79 55 12 98 45
email: marie.galay@calliditas.com
The information was sent for publication, through the agency of the contact persons set out above, on May 28, 2021 at 12:00 p.m. CET.
About Calliditas
Calliditas Therapeutics is a biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments. Calliditas successfully reported top line data of its global Phase 3 study in IgAN in November of 2020 and, if approved, aims to commercialize Nefecon in the United States on its own and partner elsewhere. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT). Visit www.calliditas.com for further information.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Jefferies Conference Press Release - En |
View original content:http://www.prnewswire.com/news-releases/calliditas-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-301301624.html
SOURCE Calliditas Therapeutics
FAQ
When is Calliditas presenting at the Jefferies Virtual Healthcare Conference?
Where can I register for the Calliditas presentation at the Jefferies Conference?
What is the focus of Calliditas Therapeutics?
What is Nefecon, the lead product candidate of Calliditas?
What is the stock symbol for Calliditas Therapeutics?
